---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-002832"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-01-17T23:59:59+00:00"
generated_at: "2026-05-27T23:30:37.916834+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants

## Summary
- Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.
- Each Pre-Funded Unit includes a pre-funded warrant (exercise $0.001) and 1.5 common warrants (exercise $1.40).
- Amended agreement requires shareholder approval before issuing >19.99% of common stock.
- Placement agents Boustead and D. Boral receive 8% cash commission plus warrants for 175,000 shares at $1.40.
- Offering closed on January 16, 2025; securities sold under Section 4(a)(2) and Rule 506(b).

## SEC filing metadata
- accession: 0001493152-25-002832
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/0001493152-25-002832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-002832
- JSON: https://secwatch.observer/filing/0001493152-25-002832.json
- Plain text: https://secwatch.observer/filing/0001493152-25-002832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.